Employees: 71
Size Larimar Therapeutics (LRMR) is a United States Health Care company (Biotechnology) with a market value of $337M, the 2978th largest of 3,085 United States companies the cockpit tracks. Shares closed at $3.23 on 18 Nov 2026.
Performance Over six months the shares fell 8.6%, against -31.0% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd highest of 20 in its peer set.
Short interest Short interest is 10.1% of the free float (30 Oct 2026).
Next results Next results expected around 19 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$301,000 | -$350,000 | -$318,000 | -$311,000 | -$272,000 |
| EBITDA | -$179M | -$172M | -$90.6M | -$41.4M | -$36.3M |
| Net income | -$173M | -$166M | -$80.6M | -$36.9M | -$35.4M |
| Free cash flow | -$156M | -$113M | -$71.3M | -$33.6M | -$27.7M |
| Capital expenditure | $153,000 | $91,000 | $515,000 | $164,000 | $100,000 |
| Total debt | $4.96M | $4.07M | $5.12M | $5.55M | $5.41M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | LRMR | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +32.2% | -4.7% | 2nd highest of 20 |
| 6-month return | -8.6% | -31.0% | 2nd highest of 20 |
| Distance from 52-week high | -49.8% | -52.1% | 9th highest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Larimar Therapeutics LRMR | United States | $337M | -9% | n/a | n/a | n/a | n/a | n/a |
| GI Innovation 358570.KS | South Korea | $339M | -47% | +1,527% | -918% | 78.5× | n/a | n/a |
| Lyell Immunopharma LYEL | United States | $341M | -19% | -63% | -1,388,360% | 13,911.5× | n/a | n/a |
| Medtide 3880.HK | Hong Kong | $331M | -17% | +14% | 36% | 2.4× | n/a | n/a |
| Aspen Neuroscience ASPE | United States | $349M | n/a | n/a | n/a | n/a | n/a | n/a |
| Laekna 2105.HK | Hong Kong | $326M | -53% | n/a | -57% | 4.7× | n/a | n/a |
| Medy-Tox 086900.KS | South Korea | $350M | -36% | +3% | 10% | 2.2× | 4.7% | +11.9% |
| C4 Therapeutics CCCC | United States | $325M | -25% | +7% | -316% | 5.4× | n/a | n/a |
| AP Biosciences 6945.TWO | Taiwan | $321M | -31% | n/a | n/a | n/a | n/a | n/a |
| IMPACT Therapeutics 7630.HK | Hong Kong | $319M | -79% | +395% | -173% | 9.5× | n/a | n/a |
| CorMedix CRMD | United States | $358M | -43% | +92% | 39% | 0.4× | n/a | n/a |
| ProKidney PROK | United States | $314M | -38% | +4% | -24,830% | 1,625.4× | n/a | n/a |
| Contineum Therapeutics CTNM | United States | $363M | -31% | n/a | n/a | n/a | n/a | n/a |
| Onconic Therapeutics 476060.KS | South Korea | $368M | -49% | +179% | 21% | 5.2× | 0.6% | +725.2% |
| Nautilus Biotechnolgy NAUT | United States | $310M | +2% | n/a | -15,106% | 588.9× | n/a | n/a |
| Cuorips 4894.T | Japan | $309M | -10% | -80% | -1,765% | 602.9× | n/a | n/a |
| Guangdong Vtr Bio-Tech 300381.SZ | China | $370M | -31% | 0% | -4% | 2.6× | n/a | n/a |
| X4 Pharmaceuticals XFOR | United States | $304M | -21% | -50% | -474% | 11.4× | n/a | n/a |
| Viva Biotech 1873.HK | Hong Kong | $303M | -18% | +7% | 10% | 1.0× | 2.6% | +19.1% |
| Greenwich LifeSciences GLSI | United States | $302M | -25% | n/a | n/a | n/a | n/a | n/a |
| PureTech Health PRTC.L | United Kingdom | $378M | -15% | -4% | -1,617% | 27.4× | n/a | n/a |